Therapeutics and COVID-19
WHO develops the most up-to-date clinical practice guidelines for the use of therapeutics for patients with COVID-19 based on ongoing assessment of new evidence generated by the international medical research community and first responders.
The WHO steering committee meets regularly to review new evidence for therapeutics and prioritize when a new guideline update will be triggered.
WHO Guideline Development Group (GDG) is made up of an expert panel of global experts, frontline providers and patient partners developing transparent and trustworthy quality COVID-19 clinical practice guidelines. – Biographies of experts: WHO Guideline Development Group Living Guidelines for COVID-19.
Rapid adaptation and implementation of WHO-recommended therapeutics into the COVID-19 clinical care pathways is essential at national and local levels to impact patient outcomes.
Current list of therapeutics under review by the GDG with tentative timelines for the publication of recommendations and upcoming meetings.
The following therapeutics are currently under review : remdesivir, nirmatrelvir-ritonavir, ivermectin and deuremidevir hydrobromide (VV116).
The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-date recommendations for the use of drugs to...
The WHO Therapeutics and COVID-19: living guideline contains the most up-to-date recommendations for the use of therapeutics in the treatment...
COVID-19 Therapeutic tools and resources for health care workers
Antivirals for non severe COVID-19 Toolbox
Therapeutics for severe and critical COVID-19 Toolbox